<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">akusherstvo</journal-id><journal-title-group><journal-title xml:lang="en">Obstetrics, Gynecology and Reproduction</journal-title><trans-title-group xml:lang="ru"><trans-title>Акушерство, Гинекология и Репродукция</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2313-7347</issn><issn pub-type="epub">2500-3194</issn><publisher><publisher-name>IRBIS LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17749/2313-7347/ob.gyn.rep.2021.256</article-id><article-id custom-type="elpub" pub-id-type="custom">akusherstvo-1097</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ОRIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group></article-categories><title-group><article-title>Features and relationships of metabolic syndrome components in men with androgen deficiency. Part 1. Are body composition parameters, sex hormone levels and blood pressure interrelated?</article-title><trans-title-group xml:lang="ru"><trans-title>Особенности и взаимосвязи компонентов метаболического синдрома у мужчин с андрогенным дефицитом. Часть 1. Взаимосвязаны ли параметры состава тела, уровень половых гормонов и АД между собой?</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7954-0437</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Павлова</surname><given-names>З. Ш.</given-names></name><name name-style="western" xml:lang="en"><surname>Pavlova</surname><given-names>Z. Sh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Павлова Зухра Шариповна – кандидат медицинских наук, врач-эндокринолог, старший научный сотрудник отдела возраст-ассоциированных заболеваний, медицинский научно-образовательный центр </p><p>119234 Москва, Ленинские горы, д. 1, стр. 12</p></bio><bio xml:lang="en"><p>Zukhra Sh. Pavlova – MD, PhD, Endocrinologist, Senior Researcher, Department of AgeAssociated Diseases, Medical Research and Education Center </p><p>1 bldg. 12, Leninskie Gory, Moscow 119234</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5939-0344</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гревина</surname><given-names>В. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Grevina</surname><given-names>V. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Гревина Валерия Юрьевна – студент 6-го курса факультета фундаментальной медицины </p><p>119234 Москва, Ленинские горы, д. 1, стр. 12</p></bio><bio xml:lang="en"><p>Valeria Yu. Grevina – 6 th year Student, Faculty of Fundamental Medicine </p><p>1 bldg. 12, Leninskie Gory, Moscow 119234</p></bio><email xlink:type="simple">grevinav@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБОУ ВО «Московский государственный университет имени М.В. Ломоносова»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>05</day><month>10</month><year>2021</year></pub-date><volume>15</volume><issue>5</issue><fpage>534</fpage><lpage>547</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Pavlova Z.S., Grevina V.Y., 2021</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="ru">Павлова З.Ш., Гревина В.Ю.</copyright-holder><copyright-holder xml:lang="en">Pavlova Z.S., Grevina V.Y.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.gynecology.su/jour/article/view/1097">https://www.gynecology.su/jour/article/view/1097</self-uri><abstract><sec><title>Introduction</title><p>Introduction. Currently, a shortage of studies demonstrating the relationship between body composition disorders in men with excess adipose tissue and metabolic syndrome (MS), depending on the level of testosterone, estradiol, sex hormone binding globulin (SHBG), anthropometric parameters, or blood pressure (BP) has been noted.</p></sec><sec><title>Aim</title><p>Aim: to examine a relationship between disturbed anthropometric parameters, level of sex hormones and BP in men with MS.</p></sec><sec><title>Materials and Methods</title><p>Materials and Methods. There were enrolled 64 overweight men to the study. The patients were divided into 3 groups based on the body mass index (BMI): group 1 – with overweight (n = 24), group 2 – with the first degree of obesity (n = 21), group 3 – with the second and third degree of obesity (n = 19). A correlation analysis was carried out between the data of bioimpedance analysis (BIA) and laboratory data, as well as additionally assessing the level of inter-group difference.</p></sec><sec><title>Results</title><p>Results. Our study allowed to find the relationship between the parameters of body composition in men with overdeveloped adipose tissue and MS that was coupled to the level of testosterone, estradiol, SHBG, anthropometric parameters as well as blood pressure indicators. A moderate negative correlation was observed across entire patient sample between the testosterone level and several anthropometric parameters: waist circumference (WC), WC/hip circumference and BMI (p &lt; 0.05). A weak negative correlation was found between the level of testosterone, fat mass (FM) and the proportion of FM in the general sample. A weak negative correlation between systolic BP and testosterone level throughout the patient sample was found, but a moderate negative correlation was observed solely in group 3. A positive weak correlation was found between testosterone and estradiol level in the general sample as well as in group 2, whereas in group 1 it was moderate. In contrast, in group 3 such a correlation was negative and weak. A positive correlation can be also traced between testosterone and SHBG level particularly being moderate in the entire sample as well as in groups 1 and 2, and noticeable in group 3.</p></sec><sec><title>Conclusion</title><p>Conclusion. The relationship was revealed between the parameters of body composition in men with excessive adipose tissue and MS related to testosterone, estradiol, SHBG level as well as anthropometric parameters and ВР corroborating systematic and multi-layered nature underlying obesity.</p></sec></abstract><trans-abstract xml:lang="ru"><sec><title>Введение</title><p>Введение. Сегодня недостаточно работ, демонстрирующих взаимосвязь между нарушениями состава тела у мужчин с избыточной жировой тканью и метаболическим синдромом (МС) в зависимости от содержания тестостерона, эстрадиола, глобулина, связывающего половые гормоны (ГСПГ), антропометрических параметров или артериального давления (АД).</p></sec><sec><title>Цель исследования</title><p>Цель исследования: изучение взаимосвязей между нарушениями антропометрических параметров, уровнем половых гормонов и АД у мужчин с МС.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В исследование были включены 64 мужчины с избыточной массой тела. Пациентов разделили на 3 группы в зависимости от индекса массы тела (ИМТ): группа 1 с избыточной массой тела (n = 24), группа 2 с ожирением I степени (n = 21), группа 3 с ожирением II и III степенями ожирения (n = 19). Проводили корреляционный анализ между результатами биоимпедансного анализа (БИА) и лабораторными данными, а также определяли уровень различий между группами.</p></sec><sec><title>Результаты</title><p>Результаты. Умеренная отрицательная корреляция прослеживалась по всей выборке между уровнем тестостерона и рядом антропометрических показателей: окружность талии (ОТ), отношение ОТ/окружность бедер (ОБ) и ИМТ (p &lt; 0,05). Между уровнем тестостерона и такими показателями БИА, как жировая масса (ЖМ) и доля ЖМ определена слабая отрицательная корреляция только в общей выборке. По всей выборке наблюдалась слабая отрицательная корреляция между систолическим АД (САД) и тестостероном, и отдельно в группе 3 установлена умеренная отрицательная корреляция. Выявлена положительная слабая корреляция между значениями тестостерона и эстрадиола в общей выборке и в группе 2; в группе 1 эта корреляция была умеренной и также положительной. В группе 3 корреляция присутствовала, но она отрицательная и слабая. Положительная корреляция прослеживалась между значениями тестостерона ГСПГ: умеренная по всей выборке и в группах 1 и 2 и заметная в группе 3.</p></sec><sec><title>Заключение</title><p>Заключение. Выявлена взаимосвязь между параметрами состава тела у мужчин с избыточно развитой жировой тканью и МС в зависимости от содержания тестостерона, эстрадиола, ГСПГ, антропометрических параметров и АД. Это подтверждает системность и многокомпонентность проблемы ожирения.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>метаболический синдром</kwd><kwd>МС</kwd><kwd>ожирение</kwd><kwd>индекс массы тела</kwd><kwd>ИМТ</kwd><kwd>артериальное давление</kwd><kwd>АД</kwd><kwd>тестостерон</kwd><kwd>эстрадиол</kwd><kwd>глобулин</kwd><kwd>связывающий половые гормоны</kwd><kwd>ГСПГ</kwd><kwd>биоимпедансный анализ</kwd><kwd>БИA</kwd></kwd-group><kwd-group xml:lang="en"><kwd>metabolic syndrome</kwd><kwd>MS</kwd><kwd>obesity</kwd><kwd>body mass index</kwd><kwd>BMI</kwd><kwd>blood pressure</kwd><kwd>BP</kwd><kwd>testosterone</kwd><kwd>estradiol</kwd><kwd>sex hormone binding globulin</kwd><kwd>SHBG</kwd><kwd>bioimpedance analysis</kwd><kwd>BIA</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Saklayen M.G. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. https://doi.org/10.1007/s11906-018-0812-z.</mixed-citation><mixed-citation xml:lang="en">Saklayen M.G. The global epidemic of the metabolic syndrome. Curr Hypertens Rep. 2018;20(2):12. https://doi.org/10.1007/s11906-018-0812-z.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Swarup S., Goyal A., Grigorova Y., Zeltser R. Metabolic syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2021 Aug 1. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459248/.</mixed-citation><mixed-citation xml:lang="en">Swarup S., Goyal A., Grigorova Y., Zeltser R. Metabolic syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan. 2021 Aug 1. Available at: https://www.ncbi.nlm.nih.gov/books/NBK459248/.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Шварц В.Я. Воспаление как фактор патогенеза инсулинорезистентности и сахарного диабета 2-го типа. Терапевтический архив. 2009;81(10):74–80.</mixed-citation><mixed-citation xml:lang="en">Schwartz V.Ya. Inflammation as a factor in the pathogenesis of insulin resistance and type 2 diabetes mellitus. [Vospalenie kak faktor patogeneza insulinorezistentnosti i saharnogo diabeta 2-go tipa. Terapevticheskij arhiv. 2009;81(10):74–80. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Шварц В.Я. Воспаление жировой ткани. Часть 1. Морфологические и функциональные проявления. Проблемы эндокринологии. 2009;55(4):44–9. https://doi.org/10.14341/probl200955444-49.</mixed-citation><mixed-citation xml:lang="en">Shvarts V.Ya. Adipose tissue inflammation. Part 1. Morphological and functional manifestations. [Vospalenie zhirovojtkani. Chast' 1. Morfologicheskie i funkcional'nye proyavleniya]. Problemy endokrinologii. 2009;55(4):44–9. (In Russ.). https://doi.org/10.14341/probl200955444-49.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Шварц В.Я. Воспаление жировой ткани. Часть 2. Патогенетическая роль при сахарном диабете 2-го типа. Проблемы эндокринологии. 2009;55(5):43–8. https://doi.org/10.14341/probl200955543-48.</mixed-citation><mixed-citation xml:lang="en">Shvarts V.Ya. Inflammation of adipose tissue. Part 2. Pathogenetic role in type 2 diabetes mellitus. [Vospalenie zhirovoj tkani. Chast' 2. Patogeneticheskaya rol' pri saharnom diabete 2-go tipa]. Problemy endokrinologii. 2009;55(5):43–8. (In Russ.). https://doi.org/10.14341/probl200955543-48.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Шварц В.Я. Воспаление жировой ткани. Часть 3. Патогенетическая роль в развитии атеросклероза. Проблемы эндокринологии. 2009;55(6):40–5. https://doi.org/10.14341/probl200955640-45.</mixed-citation><mixed-citation xml:lang="en">Shvarts V. Inflammation of adipose tissue. Part 3. Pathogenetic role in the development of atherosclerosis. [Vospalenie zhirovoj tkani. Chast' 3. Patogeneticheskaya rol' v razvitii ateroskleroza]. Problemy endokrinologii. 2009;55(6):40–5. (In Russ.). https://doi.org/10.14341/probl200955640-45.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Павлова З.Ш., Голодников И.И. Ожирение = воспаление. Патогенез. Чем это грозит мужчинам? Медицинский вестник Юга России. 2020;11(4):6–23. https://doi.org/10.21886/2219-8075-2020-11-4-6-23.</mixed-citation><mixed-citation xml:lang="en">Pavlova Z.Sh., Golodnikov I.I. Obesity = inflammation. Pathogenesis. How does this threaten men? [Ozhirenie = vospalenie. Patogenez. Chem eto grozit muzhchinam?] Medicinskij vestnik Yuga Rossii. 2020;11(4):6–23. (In Russ.). https://doi.org/10.21886/2219-8075-2020-11-4-6-23.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Carruthers M., Trinick T.R., Jankowska E., Traish A.M. Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovasc Diabetol. 2008;7:30. https://doi.org/10.1186/1475-2840-7-30.</mixed-citation><mixed-citation xml:lang="en">Carruthers M., Trinick T.R., Jankowska E., Traish A.M. Are the adverse effects of glitazones linked to induced testosterone deficiency? Cardiovasc Diabetol. 2008;7:30. https://doi.org/10.1186/1475-2840-7-30.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Cutolo M. Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2004;31(3):419–21.</mixed-citation><mixed-citation xml:lang="en">Cutolo M. Estrogen metabolites: increasing evidence for their role in rheumatoid arthritis and systemic lupus erythematosus. J Rheumatol. 2004;31(3):419–21.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Castagnetta L.A., Carruba G., Granata O.M. et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol. 2003;30(12):2597–605.</mixed-citation><mixed-citation xml:lang="en">Castagnetta L.A., Carruba G., Granata O.M. et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. J Rheumatol. 2003;30(12):2597–605.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Гамидов С.И., Шатылко Т.В., Гасанов Н.Г. Мужское здоровье и ожирение – диагностика и терапевтические подходы. Ожирение и метаболизм. 2019;16(3):29–36. https://doi.org/https://doi.org/10.14341/omet10314.</mixed-citation><mixed-citation xml:lang="en">Gamidov S.I., Shatylko T.V., Gasanov N.G. Male health and obesity – diagnostic and therapeutic approach. [Muzhskoe zdorov'e i ozhirenie – diagnostika i terapevticheskie podhody]. Ozhirenie i metabolizm. 2019;16(3):29–36. (In Russ.). https://doi.org/https://doi.org/10.14341/omet10314.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Dobroch J., Cieśluk K., Sawicka-Żukowska M. et al. Metodypomiaruskładuciała w pediatrii – przegląd. Część 1. Pediatr Endocrinol Diabetes Metab. 2018;24(4):185–90. (In Polish). https://doi.org/10.5114/pedm.2018.83365.</mixed-citation><mixed-citation xml:lang="en">Dobroch J., Cieśluk K., Sawicka-Żukowska M. et al. Metodypomiaruskładuciała w pediatrii – przegląd. Część 1. Pediatr Endocrinol Diabetes Metab. 2018;24(4):185–90. (In Polish). https://doi.org/10.5114/pedm.2018.83365.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Павлова З.Ш., Голодников И.И. Скрытое пресаркопеническое ожирение у пациента с воспалительными заболеваниями кишечника. Эндокринология: новости, мнения, обучение. 2020;9(3):59–62. https://doi.org/10.33029/2304-9529-2020-9-3-59-62.</mixed-citation><mixed-citation xml:lang="en">Pavlova Z.Sh., Golodnikov I.I. Latent presarcopenic obesity in a patient with inflammatory bowel disease. [Skrytoe presarkopenicheskoe ozhirenie u pacienta s vospalitel'nymi zabolevaniyami kishechnika]. Endokrinologiya: novosti, mneniya, obuchenie. 2020;9(3):59–62. (In Russ.). https://doi.org/10.33029/2304-9529-2020-9-3-59-62.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Павлова З.Ш., Пьяных О.П., Голодников И.И. Роль биоимпедансного анализа в определении метаболического здоровья человека. В кн.: Ожирение. Современный взгляд на патогенез и терапию: учебное пособие. Том 2. М.: ГЭОТАР-Медиа, 2021. 227–60.</mixed-citation><mixed-citation xml:lang="en">Pavlova Z.Sh., Pyanykh O.P., Golodnikov I.I. The role of bioimpedance analysis in determining the metabolic health of a person. In: Obesity. A modern view of pathogenesis and therapy: a tutorial. Volume 2. [Rol' bioimpedansnogo analiza v opredelenii metabolicheskogo zdorov'ya cheloveka. V kn.: Ozhirenie. Sovremennyj vzglyad na patogenez i terapiyu: uchebnoe posobie. Tom 2]. Moscow: GEOTAR-Media, 2021. 264 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Павлова З.Ш., Пьяных О.П., Голодников И.И. Биоимпедансный анализ: клинические примеры и интерпретация изменений состава тела человека при воздействии различных факторов. Эндокринология: новости, мнения, обучение. 2020;9(4):74–81. https://doi.org/10.33029/2304-9529-2020-9-4-74-81.</mixed-citation><mixed-citation xml:lang="en">Pavlova Z.Sh., Pyanykh O.P., Golodnikov I.I. Bioimpedance analysis: clinical examples and explanation of changes in human body composition under the influence of various factors. [Bioimpedansnyj analiz: klinicheskie primery i interpretaciya izmenenij sostava tela cheloveka pri vozdejstvii razlichnyh faktorov]. Endokrinologiya: novosti, mneniya, obuchenie. 2020;9(4):74–81. (In Russ.). https://doi.org/10.33029/2304-9529-2020-9-4-74-81.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva: World Health Organization, 2008. 47 p. Available at: https://apps.who.int/iris/handle/10665/44583.</mixed-citation><mixed-citation xml:lang="en">Waist circumference and waist-hip ratio: report of a WHO expert consultation. Geneva: World Health Organization, 2008. 47 p. Available at: https://apps.who.int/iris/handle/10665/44583.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G., Fagard R., Narkiewicz К. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc.</mixed-citation><mixed-citation xml:lang="en">Mancia G., Fagard R., Narkiewicz К. et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–357. https://doi.org/10.1097/01.hjh.0000431740.32696.cc.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Бленков Ю.Н., Привалова Е.В., Каплунова В.Ю. и др. Метаболический синдром: история развития, основные критерии диагностики. Рациональная фармакотерапия в кардиологии. 2018;14(5):757–64. https://doi.org/10.20996/1819-6446-2018-14-5-757-764.</mixed-citation><mixed-citation xml:lang="en">Blenkov Yu.N., Privalova E.V., Kaplunova V.Yu. et al. Metabolic syndrome: development of the issue, main diagnostic criteria. [Metabolicheskij sindrom: istoriya razvitiya, osnovnye kriterii diagnostiki]. Racional'naya farmakoterapiya v kardiologii. 2018;14(5):757–64. (In Russ.). https://doi.org/10.20996/1819-6446-2018-14-5-757-764.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Метаболический синдром. Под ред. член.-корр. РАМН Г.Е. Ройтберг. М.: MЕДпрессинформ, 2007. 224 c.</mixed-citation><mixed-citation xml:lang="en">Metabolic syndrome. Ed. Corresponding Member of RAMS G.E. Roitberg. [Metabolicheskij sindrom. Pod red. chlen.-korr. RAMN G.E. Rojtberga]. Moscow: MEDpress-inform, 2007. 224 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Alberti K.G., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.</mixed-citation><mixed-citation xml:lang="en">Alberti K.G., Eckel R.H., Grundy S.M. et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Kassi E., Pervanidou P., Kaltsas G., Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48. https://doi.org/10.1186/1741-7015-9-48.</mixed-citation><mixed-citation xml:lang="en">Kassi E., Pervanidou P., Kaltsas G., Chrousos G. Metabolic syndrome: definitions and controversies. BMC Med. 2011;9:48. https://doi.org/10.1186/1741-7015-9-48.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Estradiol, serum. Test Catalog. Mayo Clinic laboratories. Available at: https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/81816.</mixed-citation><mixed-citation xml:lang="en">Estradiol, serum. Test Catalog. Mayo Clinic laboratories. Available at: https://www.mayocliniclabs.com/test-catalog/Clinical+and+Interpretive/81816.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Jankowska E.A., Rozentryt P., Ponikowska B. et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009;301(18):1892–901. https://doi.org/10.1001/jama.2009.639.</mixed-citation><mixed-citation xml:lang="en">Jankowska E.A., Rozentryt P., Ponikowska B. et al. Circulating estradiol and mortality in men with systolic chronic heart failure. JAMA. 2009;301(18):1892–901. https://doi.org/10.1001/jama.2009.639.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Basu A., Seth S., Arora K. et al. Evaluating estradiol levels in male patients with colorectal carcinoma. J Clin Diagn Res: 2015;9(1):Bc08–10. https://doi.org/10.7860/jcdr/2015/10508.5397.</mixed-citation><mixed-citation xml:lang="en">Basu A., Seth S., Arora K. et al. Evaluating estradiol levels in male patients with colorectal carcinoma. J Clin Diagn Res: 2015;9(1):Bc08–10. https://doi.org/10.7860/jcdr/2015/10508.5397.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Cunningham G.R. Testosterone and metabolic syndrome. Asian J Androl. 2015;17(2):192–6. https://doi.org/10.4103/1008-682X.148068.</mixed-citation><mixed-citation xml:lang="en">Cunningham G.R. Testosterone and metabolic syndrome. Asian J Androl. 2015;17(2):192–6. https://doi.org/10.4103/1008-682X.148068.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Tanabe M., Akehi Y., Nomiyama T. et al. Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. Endocr J. 2015;62(2):123–32. https://doi.org/10.1507/endocrj.EJ14-0313.</mixed-citation><mixed-citation xml:lang="en">Tanabe M., Akehi Y., Nomiyama T. et al. Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men. Endocr J. 2015;62(2):123–32. https://doi.org/10.1507/endocrj.EJ14-0313.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Meftah N., Bijani A., Hosseini S.R., Soleimani A.M. Decreased serum testosterone level was not significantly correlated with lipid indices in elderly men. Caspian J Intern Med. 2021;12(2):135–9. https://doi.org/10.22088/cjim.12.2.135.</mixed-citation><mixed-citation xml:lang="en">Meftah N., Bijani A., Hosseini S.R., Soleimani A.M. Decreased serum testosterone level was not significantly correlated with lipid indices in elderly men. Caspian J Intern Med. 2021;12(2):135–9. https://doi.org/10.22088/cjim.12.2.135.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
